OraSure Technologies, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparisons are with Q1 2023 unless stated otherwise. OraSure develops and sells diagnostic tests and specimen-collection products, including COVID-19, HIV and hepatitis tests, molecular sample-management products, and related services.
Financial performance
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Net revenue | $54.1 million | $155.0 million; down 65% |
| Gross profit / margin | $24.1 million / 44.5% | $65.8 million / 42.5% |
| Operating income (loss) | $(7.1) million | $24.3 million |
| Net income (loss) | $(3.6) million; $(0.05) per diluted share | $27.2 million; $0.37 per diluted share |
| Cash from operating activities | $6.7 million | $6.0 million |
| Cash and cash equivalents | $247.1 million | $290.4 million at December 31, 2023 |
| Short-term investments | $16.6 million | None at December 31, 2023 |
| Working capital | $319.4 million | $346.9 million at December 31, 2023 |
| Total liabilities | $41.3 million | $52.2 million at December 31, 2023 |
There were no borrowings reported; liabilities include lease obligations. Cash and short-term investments totaled $263.8 million at quarter-end. Cash declined $43.3 million, chiefly reflecting $28.3 million invested in Sapphiros and net purchases of short-term investments. Investing cash outflow was $46.5 million; financing cash outflow was $1.3 million, including $1.5 million of share withholding-tax repurchases.
Material changes and key drivers
- COVID-19 diagnostics revenue fell 80% to $23.1 million, primarily from lower InteliSwab sales through U.S. government procurement contracts. COVID-19 remained 43% of revenue, versus 76% a year earlier.
- Diagnostics revenue, including HIV and HCV, decreased 4% to $16.4 million; molecular sample-management revenue fell 16% to $10.8 million; molecular services revenue declined 37% to $0.9 million.
- Gross margin improved to 44.5%, supported by higher average InteliSwab selling prices and lower scrap expense, partly offset by lower non-product revenue.
- Operating expenses excluding impairment charges declined $12.6 million, reflecting cost reductions and lower headcount. The company recorded $3.3 million of impairment losses, mainly related to the planned wind-down of Diversigen molecular services and Novosanis operations in Belgium.
- Other income rose to $3.5 million, primarily due to higher interest income. The company recorded a small income-tax benefit and maintained a full valuation allowance on U.S. deferred tax assets.
Outlook, risks and unusual items
- Management expects the decline in COVID-19 revenue to continue through 2024 because government-contract fulfillment is winding down and overall COVID-19 testing demand is lower. The filing provides no broader numerical revenue or earnings guidance.
- Management expects existing cash and cash equivalents to fund operating expenses and capital expenditures for at least the next 12 months. It also committed up to $30.0 million to Sapphiros, subject to conditions; $28.3 million had been funded by March 31, 2024.
- OraSure began winding down Diversigen’s microbiome sequencing-services business and its Belgian Novosanis operations; it plans to continue selling and manufacturing Colli-Pee through DNAG. It also implemented a workforce reduction, largely affecting COVID-19 manufacturing.
- A non-commercial customer represented 40% of Q1 2024 revenue and 29% of quarter-end accounts receivable. The filing also notes reliance on sole-source suppliers and third-party manufacturers.
- In patent litigation with Spectrum Solutions, the company’s appeal of a noninfringement ruling remained pending, with oral argument expected in the second half of 2024. The PTO held certain claims of a second patent unpatentable; OraSure’s rehearing request was denied, and it was considering appellate options. Review of a third patent was instituted, with oral argument scheduled for January 2025.
- The company stated that no material changes had occurred to the risk factors in its 2023 Form 10-K. Its $109 million U.S. government manufacturing-capacity contract was completed, and all funding had been received by year-end 2023.
Important facts for investors to verify
- How quickly COVID-19 contract revenue and InteliSwab demand decline, and whether other product lines can offset the reduction.
- Progress and costs of the Diversigen and Novosanis wind-downs, and whether planned cost savings and improved margins are realized.
- Terms, remaining funding conditions, and commercial impact of the Sapphiros investment and distribution agreements.
- Customer concentration, sole-source supply exposure, and developments in the Spectrum patent proceedings.
- Cash use, investment liquidity, and whether the stated 12-month funding outlook remains appropriate as operating results change.